Bone Morphogenetic
Proteins Market - Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2014 - 2022. Bone Morphogenetic Proteins Market
Expected to Reach USD 587.069 Million Globally in 2022.
To date, autograft
bone graft substitutes harvested from the patient’s own body and
allografts harvested from human cadaver or animal are considered
ideal for healing injured bone tissues. Although, autologus and
allogenic bone grafting is an effective treatment of certain spinal
disorders, the bone transplantation procedure could prolong hospital
stay, increase blood loss, recovery time, risk of infectious disease
transmission, and increased stress at the harvest site. Furthermore,
autografts are not suitable for elderly patients and allogenic bone
grafts in some cases show low bio-activity level. Thus, bone grafting
procedures are witnessing a steady shift from allogenic and autologus
bone graft substitutes to growth factors such as bone morphogenetic
proteins (BMPs) and cell-based matrices. BMPs have the ability to
stimulate new bone formation by initiating the differentiation of
stem cells into osteoblasts. The BMP products have eliminated the
need for bone harvesting and reduced the healing time. Thus, the
market for BMPs is increasing owing to better osteoinduction and
fusion rate, which have reduced the hospital stay, consequently
reducing the overhead expenses.
Browse
the full Bone Morphogenetic Proteins Market Report @ :
The global bone
morphogenetic proteins market, based on geography, is segmented into
North America, Europe, Asia Pacific, and Rest of the World (RoW). In
2013, North America accounted for the majority share of this market
globally in terms of revenue and is anticipated to retain its
position during the forecast period. Growth in this market is
expected to be driven by aging population and the desire to have an
active lifestyle. Similarly, increasing incidences of lower back
pain, which is commonly observed in people aged between 40 years and
80 years, is also a key factor that is expected to increase the
uptake of BMPs in North America. According to the National Institutes
of Health statistics, lower back pain was the most common cause of
pain, followed by migraine or headache, and neck pain in the U.S. in
2012. Moreover, 28.4% of the population of the U.S. visits physician
clinics for chronic lower back pain. Lower back pain is associated
common reason for missed work and job-related disability. Thus,
patients with back pain are advised spinal fusion procedures, if
non-surgical treatment is ineffective. Therefore, growing incidences
of lower back pain that requires spinal surgeries is expected to
propel demand for bone morphogenetic proteins in North America.
Furthermore, in North America spinal fusion surgeries accounted for
the largest share of the market at 76.5% in 2013. In addition,
according to the Agency for Healthcare Research and Quality (AHRQ),
the number of spinal fusion procedures in the U.S. increased by 72%
from 2002 (260,000) to 2011 (460,000). The European region followed
the North America bone morphogenetic proteins market globally in
2013.
Browse
the full Bone Morphogenetic Proteins Market Press Release @ :
The most promising
growth in this market is expected to emerge from the Asia-Pacific
region due to rising geriatric population, which is more prone to
orthopedic disorders and requires urgent effective care. In addition,
the rapidly evolving medical tourism industry in countries such as
India, Thailand, and Singapore, rise in disposable income, and
growing awareness about orthopedic treatment are few key reasons that
are anticipated to propel growth of the BMP market in this region.
The BMP market in RoW is underdeveloped and has not expanded due to
high cost, reimbursement challenges, and inadequate training of
surgeons. Adverse side effects associated with BMP usage have also
restricted the uptake of BMPs in these regions.
The market for bone
morphogenetic proteins is emerging and is currently occupied by only
two players, Medtronic plc and Olympus Biotech Corporation. Of the
two, in 2013 Medtronic held the lion’s share due to wide usage of
INFUSE. On the other hand, Olympus Biotech accounted for less than 7%
of the global BMP market. This is because OP-1/Opgenra is approved
for cases, where autologus bone marrow harvesting is not possible or
other treatments have failed.
Get
Free Sample Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2308
The global bone
morphogenetic proteins market is segmented as follows:
Global Bone
Morphogenetic Proteins Market Revenue, by Types
- rhBMP-2
- rhBMP-7
Global Bone
Morphogenetic Proteins Market Revenue, by Application
- Spinal Fusion
- Trauma
- Reconstructive Surgery
- Oral-Maxillofacial
Global Bone
Morphogenetic Proteins Market Revenue, by Geography
North America
- Types
- Applications
Europe
- Types
- Applications
Asia Pacific
- Types
- Applications
RoW
- Types
- Applications
About
Us :
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of
Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
No comments:
Post a Comment